Aripiprazole (Abilify)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (92)
Bipolar Disorder
NCT02918370 · University of Texas Southwestern Medical Center
2016-11 – 2023-06-30 · Bipolar Disorder, Alcoholism, Alcohol Abuse
What this study did
NCT01710709 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-11 – 2016-12 · Bipolar I
What this study did
NCT01122927 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07 – 2014-09 · Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
What this study did
NCT01520350 · Serge Beaulieu
2012-02 – 2013-06 · Bipolar Disorder, Depressive Episode
What this study did
NCT00194012 · University Hospitals Cleveland Medical Center
2004-08 – 2012-06 · Bipolar Disorder
What this study did
NCT00665366 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-06 – 2011-10 · Bipolar Disorder Mania
What this study did
NCT00194077 · University Hospitals Cleveland Medical Center
2004-08 – 2011-01 · Bipolar Disorder
What this study did
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
NCT00288353 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00221416 · University of Cincinnati
2005-06 – 2008-12 · Bipolar Disorder
What this study did
NCT00257972 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-10 – 2007-12 · Bipolar Disorder
What this study did
NCT00338273 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-12 – 2007-11 · Bipolar Disorder
What this study did
NCT00095511 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-06 – 2007-05 · Bipolar Disorder
What this study did
NCT00110461 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-03 – 2007-02 · Bipolar Disorder
What this study did
NCT00102518 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-09 – 2007-02 · Schizophrenia, Bipolar Disorder
What this study did
NCT00097266 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-12 – 2007-01 · Bipolar Disorder
What this study did
NCT00094432 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-06 – 2006-11 · Bipolar I Disorder
What this study did
NCT00036348 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2000-03 – 2003-06 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT01655706 · University Health Network, Toronto
2012-04-23 – 2017-01 · Major Depressive Disorder
What this study did
NCT01421342 · VA Office of Research and Development
2012-12 – 2016-06 · Major Depressive Disorder
What this study did
NCT00876343 · Otsuka Pharmaceutical Co., Ltd.
2009-03 – 2012-07 · Major Depressive Disorder
What this study did
NCT00882362 · Otsuka Pharmaceutical Co., Ltd.
2009-03 – 2012-07 · Major Depressive Disorder
What this study did
NCT01111552 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07-29 – 2011-09-27 · Major Depressive Disorder (MDD)
What this study did
NCT01123707 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-11-18 – 2011-09-27 · Major Depressive Disorder (MDD)
What this study did
NCT01111539 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07-13 – 2011-09-20 · Major Depressive Disorder (MDD)
What this study did
NCT01111565 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-10-04 – 2011-09-01 · Major Depressive Disorder (MDD)
What this study did
NCT00276978 · University Hospital Freiburg
2005-06 – 2009-11 · Therapy-resistant Depression
What this study did
NCT00683852 · Massachusetts General Hospital
2008-09 – 2009-09 · Major Depressive Disorder
What this study did
NCT00105196 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-03 – 2008-03 · Major Depressive Disorder
What this study did
NCT00556140 · Massachusetts General Hospital
2003-06 – 2008-01 · Psychotic Depression
What this study did
NCT00095745 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-09 – 2007-11 · Major Depressive Disorder
What this study did
NCT00080314 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-01 – 2006-10 · Bipolar Disorder
What this study did
Schizophrenia
NCT03510325 · Shanghai Mental Health Center
2019-02-12 – 2023-09-27 · Schizophrenia
What this study did
NCT03172871 · Otsuka Beijing Research Institute
2017-05-15 – 2019-09-30 · Schizophrenia
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT01942148 · Otsuka Pharmaceutical Co., Ltd.
2010-08 – 2015-11 · Schizophrenia
What this study did
NCT01959035 · H. Lundbeck A/S
2013-10 – 2015-03 · Schizophrenia
What this study did
NCT01795547 · H. Lundbeck A/S
2013-02 – 2014-09 · Schizophrenia
What this study did
NCT02054702 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-02 – 2014-07 · Schizophrenia
What this study did
NCT01149655 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-07 – 2013-12 · Schizophrenia
What this study did
NCT01432444 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-09 – 2013-12 · Schizophrenia
What this study did
NCT00731549 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-12 – 2013-11 · Schizophrenia
What this study did
Phase 2/3 (5)
Schizophrenia
NCT03485417 · The University of Hong Kong
2019-06-01 – 2025-05-31 · Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
What this study did
NCT01942161 · Otsuka Pharmaceutical Co., Ltd.
2010-08 – 2014-11 · Schizophrenia
What this study did
NCT00237874 · Yale University
2004-02 – 2007-02 · Schizophrenia, Psychosis
What this study did
Other / comorbidity
NCT00884884 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2007-09 – 2015-10 · Alcohol Dependence
What this study did
NCT00910780 · Washington University School of Medicine
2009-11 – 2009-11 · Diabetes
What this study did
Phase 2 (21)
Major Depressive Disorder
NCT07810738 · Washington University School of Medicine
2026-11-01 – 2029-09-15 · Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
What this study did
NCT02722967 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-03 – 2016-09 · Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did
Schizophrenia
NCT02462473 · Janssen Research & Development, LLC
2015-05 – 2016-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00737256 · Paul Saenger
2008-08 – 2014-05 · Schizophrenia, Cocaine Dependence
What this study did
NCT00202007 · Otsuka Beijing Research Institute
2005-02 – 2005-07 · Schizophrenia
What this study did
Other / comorbidity
NCT04539951 · Shanghai Mental Health Center
2020-09-22 – 2028-12-31 · Obsessive-Compulsive Disorder
What this study did
NCT07714213 · Christiana Franke
2026-10-01 – 2028-12-31 · Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
What this study did
NCT05545891 · University of Chicago
2026-06 – 2027-12 · Trichotillomania (Hair-Pulling Disorder), Dermatillomania
What this study did
NCT02574741 · University of California, Los Angeles
2012-06 – 2019-12 · Autism Spectrum Disorder
What this study did
NCT00489866 · Durham VA Medical Center
2007-03 – 2014-12 · PTSD
What this study did
NCT00619190 · University of North Carolina, Chapel Hill
2006-01 – 2012-06 · Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder
What this study did
NCT00497055 · San Francisco Department of Public Health
2009-03 – 2012-03 · Substance Abuse, HIV Infections
What this study did
NCT00208533 · Drexel University College of Medicine
2004-02 – 2011-11-16 · Autism
What this study did
NCT00667875 · Medical University of South Carolina
2008-04 – 2011-05 · Alcohol Dependence
What this study did
NCT00420459 · Indiana University
2007-04 – 2010-03 · Fragile X Syndrome
What this study did
NCT00279409 · New York State Psychiatric Institute
2006-07 – 2009-02 · Attention Deficit Hyperactivity Disorder
What this study did
NCT00308074 · Cambridge Health Alliance
2006-02 – 2009-02 · Autism, Asperger's Disorder, Pervasive Developmental Disorder
What this study did
NCT00373880 · New York State Psychiatric Institute
2005-04 – 2008-09 · Cocaine Abuse
What this study did
NCT00198055 · Indiana University
2005-01 – 2007-09 · Asperger's Disorder, Pervasive Developmental Disorder
What this study did
NCT00183235 · Medical University of South Carolina
2005-06 – 2006-02 · Alcohol Dependence
What this study did
NCT00174876 · State University of New York - Upstate Medical University
2004-07 – 2005-05 · Depression
What this study did
Phase 1/2 (2)
Schizophrenia
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
Phase 1 (25)
Bipolar Disorder
NCT03854409 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-01-31 – 2020-02-20 · Schizophrenia, Bipolar I Disorder
What this study did
NCT02087579 · Janssen Research & Development, LLC
2014-02 – 2014-12 · Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
What this study did
NCT00321516 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-02 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT03790085 · Tianjin Medical University General Hospital
2018-09-01 – 2020-12-31 · Schizophrenia, Major Depressive Disorder, Anxiety Disorders
What this study did
Schizophrenia
NCT03150771 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2017-06-14 – 2018-05-02 · Schizophrenia
What this study did
NCT02501109 · CMG Pharmaceutical Co. Ltd
2015-10 – 2016-03 · Schizophrenia
What this study did
NCT01646827 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-05 – 2013-04 · Schizophrenia
What this study did
NCT01552772 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-01 – 2012-04 · Schizophrenia
What this study did
NCT00466310 · Duke University
2007-02 – 2011-01 · Schizophrenia
What this study did
NCT01870999 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11 – 2008-10 · Schizophrenia
What this study did
NCT00102479 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07-01 – 2005-07-01 · Schizophrenia, Mania
What this study did
Other / comorbidity
NCT07215884 · University of California, San Francisco
2025-09-30 – 2027-08-30 · Stuttering, Adult
What this study did
NCT02634463 · Janssen Research & Development, LLC
2015-11-09 – 2016-11-09 · Immunoassay, Antipsychotic
What this study did
NCT02088697 · Otsuka Pharmaceutical Co., Ltd.
2013-12 – 2014-01 · Healthy Volunteers
What this study did
NCT00780702 · National Institute on Drug Abuse (NIDA)
2008-05-08 – 2013-04-16 · Cocaine Dependence, Cocaine-Related Disorders, Opioid-Related Disorders
What this study did
NCT01607762 · Janssen Research & Development, LLC
2012-02 – 2012-10 · Healthy
What this study did
NCT00276874 · Craig Rush
2006-01 – 2012-01 · Cocaine-Related Disorders
What this study did
NCT01424449 · GlaxoSmithKline
2010-01 – 2010-07 · Depressive Disorder
What this study did
NCT00689559 · AstraZeneca
2008-03 – 2009-04 · Alzheimer's Disease
What this study did
NCT00361790 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-08 – 2006-11 · Healthy
What this study did
NCT00362271 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-08 – 2006-09 · Healthy
What this study did
NCT00089440 · National Institute on Drug Abuse (NIDA)
2004-06 – 2005-03 · Amphetamine-Related Disorders
What this study did
Phase 4 (122)
Bipolar Disorder
NCT06433635 · Massachusetts General Hospital
2024-10-01 – 2030-02-28 · Bipolar I Disorder, Depression
What this study did
NCT01710163 · University of Sao Paulo
2012-06 – 2015-06 · Bipolar I Disorder
What this study did
NCT00484471 · Korea Otsuka International Asia Arab
2007-10 – 2012-11 · Bipolar Disorder
What this study did
NCT00845988 · Seoul National University Hospital
2008-12 – 2012-03 · Bipolar Disorders, Metabolic Complication
What this study did
NCT00205699 · Washington University School of Medicine
2006-04 – 2011-07 · Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
What this study did
NCT00545675 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-12 – 2010-07 · Bipolar Disorder
What this study did
NCT00545142 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-10 – 2010-06 · Bipolar Disorder
What this study did
NCT00592683 · Massachusetts General Hospital
2007-12 – 2010-04 · Pediatric Bipolar Disorder
What this study did
NCT00261443 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-09 – 2009-10 · Bipolar Disorder
What this study did
NCT00223496 · The University of Texas Health Science Center at San Antonio
2004-09 – 2009-09 · Bipolar Disorder
What this study did
NCT00277212 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-12-01 – 2009-07-01 · Bipolar Disorder
What this study did
NCT00305370 · Federal University of Rio Grande do Sul
2005-08 – 2008-03 · Bipolar Disorder, Attention Deficit Hyperactivity Disorder
What this study did
NCT00224822 · New Mexico VA Healthcare System
2004-03 – 2007-03 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
What this study did
NCT00181779 · Massachusetts General Hospital
2003-02 – 2006-12 · Bipolar Disorder, Mania
What this study did
NCT00194038 · University Hospitals Cleveland Medical Center
2004-04 – 2006-06 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT07011693 · Xinyu Zhou
2025-06-20 – 2027-12 · Major Depressive Disorder (MDD)
What this study did
NCT05531591 · Centre for Addiction and Mental Health
2019-08-01 – 2024-07-31 · Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
What this study did
NCT02977299 · Massachusetts General Hospital
2017-07-13 – 2022-04-24 · Treatment Resistant Major Depressive Disorder
What this study did
NCT02960763 · Washington University School of Medicine
2017-02-24 – 2021-09-01 · Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
What this study did
NCT01696617 · Seoul National University Hospital
2012-02-10 – 2019-02 · Major Depressive Disorder
What this study did
NCT03643159 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-06-28 – 2018-10-17 · Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
What this study did
NCT01942187 · New York State Psychiatric Institute
2013-08 – 2015-12 · Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)
What this study did
NCT01429831 · Taiwan Otsuka Pharm. Co., Ltd
2011-09 – 2013-05 · Major Depressive Disorder
What this study did
NCT00608543 · University of Texas Southwestern Medical Center
2005-10 – 2009-01 · Major Depressive Disorder
What this study did
NCT00220636 · St. Luke's-Roosevelt Hospital Center
2005-03 – 2008-01 · Depressive Disorder, Major
What this study did
NCT00208169 · Creighton University
2005-03 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
What this study did
Schizophrenia
NCT06969755 · Northwell Health
2024-09-04 – 2030-07-30 · Schizophenia Disorder
What this study did
NCT06060886 · Consorcio Centro de Investigación Biomédica en Red (CIBER)
2023-11-01 – 2025-12-31 · Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders, Diabetes, NAFLD, Psychosis
What this study did
NCT06236451 · All India Institute of Medical Sciences, Bhubaneswar
2024-04-05 – 2025-11-12 · Schizophrenia
What this study did
NCT05322031 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2022-08-01 – 2024-11-30 · Schizophrenia, Myelin Degeneration, Cognition Disorder
What this study did
NCT05766540 · All India Institute of Medical Sciences, Bhubaneswar
2023-08-20 – 2023-12-31 · Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia
What this study did
NCT04446234 · Shanghai Mental Health Center
2021-05 – 2022-12-31 · Schizophrenia
What this study did
NCT03090503 · Fundación Marques de Valdecilla
2014-06 – 2021-06 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT03289026 · Peking University
2017-09-01 – 2021-02-02 · Acute Schizophrenia Episode
What this study did
NCT02339844 · University of Copenhagen
2014-01 – 2021-01 · Schizophrenia
What this study did
NCT03883204 · Fundación Marques de Valdecilla
2015-01-01 – 2020-12 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT02532491 · Fundación Marques de Valdecilla
2014-05 – 2020-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT03839251 · Chonbuk National University Hospital
2018-06-01 – 2020-09-30 · Schizophrenia
What this study did
NCT02146547 · UMC Utrecht
2015-02 – 2020-08-26 · Schizophrenia
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT02697045 · Abdi İbrahim Otsuka
2017-01-04 – 2018-03-31 · Schizophrenia
What this study did
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01446328 · Haukeland University Hospital
2011-10 – 2017-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT01913327 · University of California, San Francisco
2013-04 – 2017-01 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00320671 · Northwell Health
2005-12 – 2015-12 · Schizophrenia
What this study did
NCT02526030 · Fundación Marques de Valdecilla
2008-10 – 2015-06 · Schizophrenia, Psychotic Disorders
What this study did
NCT02305823 · Fundación Marques de Valdecilla
2005-10 – 2014-05 · Schizophrenia, Psychotic Disorders
What this study did
NCT01164059 · University of Bremen
2010-02 – 2014-03 · Schizophrenia
What this study did
Early phase / not applicable (36)
Bipolar Disorder
NCT00531518 · MaineHealth
2007-10 – 2013-09 · Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
What this study did
NCT00746252 · University of Maryland, Baltimore
2008-06 – 2010-10 · Bipolar Disorder
What this study did
NCT00665444 · University of Pittsburgh
2008-04 – 2009-08 · Bipolar Disorder, Metabolic Syndrome
What this study did
NCT00288366 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00116259 · Federal University of Rio Grande do Sul
2005-03 – 2008-02 · Bipolar Disorder, Attention Deficit Hyperactivity Disorder
What this study did
NCT00226317 · Cambridge Health Alliance
2004-04 – 2008-02 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT06937476 · Central South University
2025-05-08 – 2026-04-29 · Major Depressive Disorder (MDD), Rumination
What this study did
NCT05389046 · Peking University
2022-08-15 – 2025-12 · Outpatients / Inpatients With Depression
What this study did
NCT06372210 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2023-06-26 – 2023-07-19 · Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did
NCT01488266 · Korea University
2011-11 – 2013-03 · Major Depressive Disorder
What this study did
NCT00953745 · Washington University School of Medicine
2009-05 – 2012-12 · Major Depressive Disorder
What this study did
NCT00873795 · Chimei Medical Center
2007-04 – 2009-03 · Major Depressive Disorder
What this study did
Schizophrenia
NCT02926976 · Shanghai Mental Health Center
2016-11 – 2019-09 · Schizophrenia
What this study did
NCT02007928 · Centre Hospitalier Universitaire de Nice
2013-04 – 2017-07 · Dissociative Disorders, Schizophrenia
What this study did
NCT02717130 · Florida Atlantic University
2016-06-08 – 2017-05-25 · Schizophrenia
What this study did
NCT01338298 · University of Maryland, Baltimore
2011-01 – 2016-12 · Hyperprolactinemia
What this study did
NCT01154829 · University of Copenhagen
2008-12 – 2016-05 · Schizophrenia
What this study did
NCT02013232 · Beijing HuiLongGuan Hospital
2013-02 – 2014-02 · Schizophrenia
What this study did
NCT00209027 · Emory University
2005-04 – 2011-04 · Schizophrenia
What this study did
NCT01057849 · Peking University
2008-09 – 2011-03 · Schizophrenia
What this study did
NCT00567099 · New Mexico VA Healthcare System
2003-08 – 2008-09 · Schizophrenia, Sensory Gating
What this study did
NCT00374348 · Jamaica Hospital Medical Center
2005-03 – 2008-05 · Schizophrenia OCD, Obsessive Compulsive Disorder
What this study did
NCT00169949 · Northwell Health
2004-01 – 2006-05 · Prodromal Schizophrenia, Prodromal Psychosis
What this study did
NCT00211380 · Louisiana State University Health Sciences Center Shreveport
2003-08 – 2006-02 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00211302 · Louisiana State University Health Sciences Center Shreveport
2003-08 – 2006-02 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT05868720 · All India Institute of Medical Sciences, Bhubaneswar
2023-07-01 – 2025-03-02 · The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
What this study did
NCT04765085 · Children's Hospital of Fudan University
2021-03 – 2022-09 · Tic Disorders
What this study did
NCT03232710 · Chengdu Kanghong Pharmaceutical Group Co., Ltd.
2017-06-26 – 2018-06-30 · Bioequivalence
What this study did
NCT03358277 · Tri-Service General Hospital (TSGH)
2014-11-19 – 2017-08-12 · Disruptive Mood Dysregulation Disorder
What this study did
NCT02137616 · Central South University
2012-06 – 2014-12 · Psychotic Disorders
What this study did
NCT00956189 · National Taiwan University Hospital
2009-11 – 2012-10 · Metabolic Syndrome X
What this study did
NCT01562808 · Seoul National University Hospital
2009-01 – 2012-01 · Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
What this study did
NCT00947154 · Stanford University
2009-07 – 2010-07 · Trichotillomania
What this study did
NCT00468130 · University of Medicine and Dentistry of New Jersey
2006-05 – 2009-11 · Autism
What this study did
NCT00223418 · The University of Texas Health Science Center at San Antonio
2004-01 – 2007-06 · Schizophenia Disorder, Schizoaffective Disorder
What this study did
NCT00282139 · University of Florida
2004-01 – 2006-10 · Tourette's Syndrome
What this study did
Used as active comparator (34)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Major Depressive Disorder
NCT07153406 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2025-09-15 – 2029-01-15 · Depressive Disorder
What this study did
Schizophrenia
NCT06589817 · Chengdu Kanghong Pharmaceutical Group Co., Ltd.
2024-10 – 2026-12 · Acute Schizophrenia
What this study did
NCT06799559 · Qilu Pharmaceutical Co., Ltd.
2025-10-02 – 2026-12 · Schizophrenia
What this study did
NCT03198078 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2017-06-30 – 2023-04-03 · Schizophrenia
What this study did
NCT03874494 · Otsuka Beijing Research Institute
2019-11-27 – 2021-09-06 · Schizophrenia
What this study did
NCT01328093 · Denovo Biopharma LLC
2011-04 – 2012-10 · Schizophrenia
What this study did
NCT01009047 · Janssen Research & Development, LLC
2009-12 – 2012-06 · Schizophrenia
What this study did
NCT01104766 · Forest Laboratories
2010-04-23 – 2011-12-20 · Schizophrenia
What this study did
Phase 2/3 (1)
Schizophrenia
NCT01129674 · Denovo Biopharma LLC
2010-06 – 2012-10 · Schizophrenia
What this study did
Phase 2 (6)
Schizophrenia
NCT07703956 · Vigonvita Life Sciences
2026-07-31 – 2027-12-31 · Schizophrenia
What this study did
NCT07550387 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-05-23 – 2026-01-19 · SCHIZOPHRENIA 1 (Disorder)
What this study did
NCT01490086 · Reviva Pharmaceuticals
2011-12 – 2013-03 · Acute Schizophrenia, Schizoaffective Disorder
What this study did
NCT00845026 · Denovo Biopharma LLC
2009-03 – 2010-12 · Schizophrenia
What this study did
NCT00905307 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-07 – 2010-11 · Schizophrenia
What this study did
Phase 1 (4)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT01354353 · Denovo Biopharma LLC
2011-05 – 2012-03 · Schizophrenia
What this study did
Other / comorbidity
NCT05532254 · Future University in Egypt
2021-02-14 – 2021-03-11 · Healthy Subjects
What this study did
Phase 4 (11)
Major Depressive Disorder
NCT05554627 · VA Office of Research and Development
2023-10-27 – 2023-10-27 · Depressive Disorder, Major
What this study did
NCT00926835 · Ministry of Health & Welfare, Korea
2009-05 – 2015-07 · Major Depressive Disorder
What this study did
Schizophrenia
NCT06501339 · All India Institute of Medical Sciences, Bhubaneswar
2024-08-10 – 2026-03-31 · Clozapine Resistant Schizophrenia
What this study did
NCT04203056 · University of California, Los Angeles
2019-12-16 – 2022-10-01 · Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
What this study did
NCT01157351 · Janssen Scientific Affairs, LLC
2010-05 – 2013-12 · Schizophrenia
What this study did
NCT01193166 · Ortho-McNeil Janssen Scientific Affairs, LLC
2010-08 – 2012-09 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00352339 · Inje University
2006-08 – 2010-12 · Schizophrenia
What this study did
NCT00299702 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2009-01 · Schizophrenia, Psychotic Disorders
What this study did
Other / comorbidity
NCT05361993 · Children's Hospital of Fudan University
2024-06-01 – 2024-12-31 · Tic Disorders
What this study did
NCT00685334 · New York State Psychiatric Institute
2003-11 – 2006-09 · Eating Disorders
What this study did
Early phase / not applicable (3)
Schizophrenia
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
Other / comorbidity
NCT06581302 · Shanghai Jiao Tong University School of Medicine
2024-09-01 – 2025-12-30 · Psychotic Disorders
What this study did
NCT02955654 · Shanghai Mental Health Center
2017-09-01 – 2018-12 · Obsessive-Compulsive Disorder
What this study did
Appears in other studies (17)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Bipolar Disorder
NCT01567527 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-08 – 2016-04 · Bipolar I Disorder
What this study did
Schizophrenia
NCT01129882 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-06-24 – 2018-12-06 · Schizophrenia
What this study did
NCT01683058 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-01 – 2014-02 · Schizophrenia
What this study did
NCT01663532 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-10 – 2013-09 · Schizophrenia
What this study did
Phase 2 (2)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Phase 1 (3)
Schizophrenia
NCT03287505 · Otsuka Beijing Research Institute
2017-06-23 – 2019-11-08 · Schizophrenia
What this study did
NCT03285503 · Otsuka Beijing Research Institute
2018-08-17 – 2019-10-14 · Schizophrenia
What this study did
NCT01909466 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-07 – 2014-04 · Schizophrenia, Mental Disorder, Nervous System Diseases
What this study did
Phase 4 (5)
Bipolar Disorder
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
Schizophrenia
NCT03376763 · Korea Otsuka Pharmaceutical Co., Ltd.
2017-11-21 – 2021-11-19 · Schizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole
What this study did
NCT02237417 · University of Utah
2014-09-01 – 2020-07-30 · Schizophrenia
What this study did
NCT02360319 · Vanguard Research Group
2014-12-11 – 2019-03-31 · Schizophrenia
What this study did
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
Early phase / not applicable (2)
Schizophrenia
NCT07547384 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2026-04-05 – 2027-11-05 · Schizophrenia
What this study did
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aripiprazole (Abilify): this drugApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Haloperidol
ApprovedUS marketing discontinued
Small moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Risperidone (QUAR)Phase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (CSPC)
—(overall)
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Weak signal
NCT03892889: Percentage of Participants With Inpatient Psychiatric Hospitalization (Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)): Abilify MyCite® 0%
AVP-786DiscontinuedCombinationsigma-1/NMDAnot yet gradedNo reviewed efficacy summary in this indication
Clozapine (Fazaclo)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 3 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Aripiprazole (Abilify) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
2027 (4)
June 2027 (3)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2027-06 · NCT07011693 · CT.gov ↗
What to watch
Phase 1Stuttering, AdultRecruiting
Est. primary completion 2027-06-30 · NCT07215884 · CT.gov ↗
What to watch
Phase 2Obsessive-Compulsive DisorderRecruiting
Est. primary completion 2027-06-30 · NCT04539951 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Trichotillomania (Hair-Pulling Disorder), DermatillomaniaNot yet recruiting
Est. primary completion 2027-12 · NCT05545891 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)Not yet recruiting
Est. primary completion 2028-05-15 · NCT07714213 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 2Major Depressive DisorderNot yet recruiting
Est. primary completion 2029-03-15 · NCT07810738 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Psychosis; AcuteRecruiting
Est. primary completion 2029-12-01 · NCT07483294 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
Phase 4Bipolar DisorderActive not recruiting
Est. primary completion 2030-02-28 · NCT06433635 · CT.gov ↗
What to watch
July 2030 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2030-07-30 · NCT06969755 · CT.gov ↗
What to watch

See the full readout calendar ↗